[go: up one dir, main page]

PL3826667T3 - Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu - Google Patents

Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu

Info

Publication number
PL3826667T3
PL3826667T3 PL18857242.4T PL18857242T PL3826667T3 PL 3826667 T3 PL3826667 T3 PL 3826667T3 PL 18857242 T PL18857242 T PL 18857242T PL 3826667 T3 PL3826667 T3 PL 3826667T3
Authority
PL
Poland
Prior art keywords
claudin6
antibodies
methods
treating cancer
cancer
Prior art date
Application number
PL18857242.4T
Other languages
English (en)
Inventor
Dylan CONKLIN
Dennis Slamon
Neil O'Brien
Mike PALAZZOLO
Erika VON EUW
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL3826667T3 publication Critical patent/PL3826667T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
PL18857242.4T 2017-09-18 2018-09-18 Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu PL3826667T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Publications (1)

Publication Number Publication Date
PL3826667T3 true PL3826667T3 (pl) 2024-09-30

Family

ID=65723110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18857242.4T PL3826667T3 (pl) 2017-09-18 2018-09-18 Przeciwciała przeciwko klaudynie6 i sposoby leczenia nowotworu

Country Status (22)

Country Link
US (4) US20200291111A1 (pl)
EP (2) EP3826667B1 (pl)
JP (2) JP7599332B2 (pl)
KR (2) KR102793719B1 (pl)
CN (2) CN111565744B (pl)
AU (2) AU2018334434B2 (pl)
BR (1) BR112020005196A2 (pl)
CA (1) CA3076207A1 (pl)
CZ (1) CZ2021138A3 (pl)
DK (1) DK3826667T3 (pl)
ES (1) ES2986343T3 (pl)
FI (1) FI3826667T3 (pl)
GB (1) GB202103867D0 (pl)
HU (1) HUE067603T2 (pl)
IL (2) IL313238A (pl)
MX (2) MX2020002921A (pl)
NO (1) NO20210351A1 (pl)
PL (1) PL3826667T3 (pl)
PT (1) PT3826667T (pl)
SG (1) SG11202002114RA (pl)
SI (1) SI3826667T1 (pl)
WO (1) WO2019056023A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111565744B (zh) * 2017-09-18 2024-12-31 加利福尼亚大学董事会 紧密连接蛋白6抗体和治疗癌症的方法
IL301638B2 (en) 2017-09-29 2024-09-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン6二重特異性抗体
MX2021011330A (es) 2019-03-20 2021-12-10 Univ California Anticuerpos de claudina-6 y conjugados de fármacos.
JP2023529557A (ja) * 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗enpp1抗体の阻害
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
US20250042996A1 (en) * 2021-11-16 2025-02-06 Christopher Bebbington Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
IL319951A (en) 2022-11-30 2025-05-01 Integral Molecular Inc Antibodies targeting claudin 6, including its bispecific formats
WO2024243561A1 (en) 2023-05-25 2024-11-28 The Regents Of The University Of California Methods of treating cancer
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
CN1296417A (zh) 1998-02-10 2001-05-23 卫福有限公司 控释制剂
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Vipアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
JP2004511425A (ja) 2000-02-08 2004-04-15 ザ ペン ステート リサーチ ファウンデーション 免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
AU2007332473B2 (en) * 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
SG187457A1 (en) * 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
JP6276176B2 (ja) 2011-05-13 2018-02-07 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のための抗体
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
RU2016122041A (ru) * 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
SI3514172T1 (sl) 2014-04-01 2020-07-31 Biontech Cell & Gene Therapies Gmbh Claudin-6 specifični imunoreceptorji in T-celični epitopi
CN111565744B (zh) * 2017-09-18 2024-12-31 加利福尼亚大学董事会 紧密连接蛋白6抗体和治疗癌症的方法

Also Published As

Publication number Publication date
SG11202002114RA (en) 2020-04-29
AU2018334434B2 (en) 2025-01-23
IL273196B1 (en) 2024-07-01
NO20210351A1 (en) 2021-03-18
JP2024150445A (ja) 2024-10-23
US20250333501A1 (en) 2025-10-30
GB202103867D0 (en) 2021-05-05
US20240400674A1 (en) 2024-12-05
SI3826667T1 (sl) 2024-09-30
KR102793719B1 (ko) 2025-04-08
PT3826667T (pt) 2024-08-02
US20200291111A1 (en) 2020-09-17
CA3076207A1 (en) 2019-03-21
JP7599332B2 (ja) 2024-12-13
IL313238A (en) 2024-07-01
WO2019056023A3 (en) 2019-05-16
MX2020002921A (es) 2020-09-28
ES2986343T3 (es) 2024-11-11
EP3826667A4 (en) 2022-07-27
MX2025012685A (es) 2025-11-03
KR20250050137A (ko) 2025-04-14
FI3826667T3 (fi) 2024-07-22
CN111565744A (zh) 2020-08-21
CN118667021A (zh) 2024-09-20
IL273196B2 (en) 2024-11-01
AU2025200467A1 (en) 2025-04-10
WO2019056023A2 (en) 2019-03-21
KR20200070238A (ko) 2020-06-17
CZ2021138A3 (cs) 2021-09-15
CN111565744B (zh) 2024-12-31
EP3826667B1 (en) 2024-04-17
EP3826667A2 (en) 2021-06-02
US20220372134A1 (en) 2022-11-24
EP4435009A2 (en) 2024-09-25
DK3826667T3 (da) 2024-07-22
HUE067603T2 (hu) 2024-10-28
JP2020536507A (ja) 2020-12-17
AU2018334434A1 (en) 2020-04-02
IL273196A (en) 2020-04-30
BR112020005196A2 (pt) 2020-09-15
EP4435009A3 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL275663A (en) Cancer treatment methods
IL289663A (en) Claudin 18 antibodies and methods for cancer treatment
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
SG10202110594UA (en) Methods of treating tumor
IL256025A (en) Methods of diagnosing and treating cancer
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL262342A (en) Cancer treatment methods
IL277981A (en) Cancer treatment methods
ZA201802481B (en) Novel biomarkers and methods of treating cancer
IL323981A (en) Cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
IL272810A (en) Methods for diagnosing and treating lung cancer
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
ZA202002144B (en) Antibodies and methods of use
SG11202005163PA (en) Methods of treating cancer
EP3585819A4 (en) ANTIBODY CONSTRUCTIONS AND CANCER TREATMENT METHODS
IL269123A (en) Methods of treating cancer
GB201609402D0 (en) Materials and methods for treating cancer
HK40053388B (en) Claudin6 antibodies and methods of treating cancer
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer